Abstracts from 2014 through the most recent CROI can be viewed in this searchable database once they have been presented at the conference. Abstract Contents: The searchable database includes abstract text as submitted by the authors prior to CROI. Study data might be updated during the presentation at CROI. Please refer to the electronic poster or webcast for updates. Searching the Abstract Database: Enter the criteria below and click the “Search” button. After the search has been entered, the results will appear below the search form.
CROI conference materials (eg, the conference program, Abstract eBook, electronic posters, CROI logo, etc) are protected by copyright. Permission to replicate or reproduce these elements, in whole or in part, must be obtained from the CROI Conference Manager, the International Antiviral Society-USA (IAS-USA). Study data (including figures within abstracts or electronic posters) are the property of the study authors. Permission to use data and figures cannot be given by IAS–USA unless it is for regulatory reasons. For more information, please email CROIabstracts@iasusa.org.
1277 Results
Background Cabotegravir + rilpivirine long-acting (CAB+RPV LA) injectable was FDA approved for treatment experienced, suppressed (viral load [VL] <50 c/mL) people with HIV (PWH) on a monthly (Q1M; 2021) or every 2 months (Q2M; 2022) schedule. We assessed CAB+RPV LA use in a real-world setting over its first 3 years of availability. Methods Suppressed adults with HIV…
Background HIV-1 protease (PR) is initially synthesized as part of the Gag-Pol polyprotein precursor, which undergoes regulated autoprocessing to produce free mature PR, essential for viral particle maturation and infectivity. We previously demonstrated that precursors and mature PRs have distinct enzymatic properties, as precursors are up to 1,000-fold less-sensitive to protease inhibitors (PIs) compared to…
Background Persistent immune activation underlies the increased risk of comorbidities during HIV treatment. Limited evidence exists on whether initiating treatment with two drugs differs from three-drug regimens in this regard. Here, we investigated the effects of DTG/3TC vs. BIC/F/TAF on inflammatory signatures in a large prospective cohort of ART-naive people living with HIV (PWH). Methods…
Background Both immunization and nirmatrelvir-ritonavir treatment (NMV-r) are known to lower the risk of severe COVID-19 including hospitalization or death. However, it is unclear whether the effect of NMV-r and acquired immunity (via vaccination or prior viral exposure indicated as serologic positivity) are additive or synergistic. Methods Non-hospitalized symptomatic adults infected with COVID-19 were enrolled into…
Background The WHO recommends dolutegravir (DTG) instead of ritonavir-boosted lopinavir (LPV/r) in second-line antiretroviral therapy (ART), and recycled tenofovir disoproxil fumarate (TDF)/emtricitabine or lamivudine (XTC) instead of zidovudine (AZT)/XTC as backbone. However, there is little long-term data from routine, low-resource settings, where DTG resistance may be emerging. We compared 24-month outcomes with these 3 regimens.…
Background SARS-CoV-2 papain-like protease (PLpro) represents a promising target for novel COVID-19 therapeutics due to its essential roles in viral replication and dysregulation of host innate immunity. PLpro is a domain of SARS-CoV-2 non-structural protein 3 (Nsp3) and is one of two cysteine proteases encoded by the virus. Currently, there are no SARS-CoV-2 PLpro inhibitors in clinical…
Background The high potency and genetic barrier of BIC/TAF/FTC (BETAF), and the long-half lives of their components could allow for longer than once-daily dosing (OD) with low risk of developing resistance mutations. We assessed the feasibility of reducing BETAF OD to 3 (3W), 2 (2W), or 1 (1W) doses per week. Methods Pilot randomized controlled…
Background We sought to examine reasons for discontinuation of long-acting injectable cabotegravir/rilpivirine (LA-CAB/RPV) and subsequent clinical outcomes in a cohort of people with HIV (PWH) in routine care. Methods We conducted a retrospective chart review of PWH who initiated LA-CAB/RPV at Ward 86 in San Francisco through April 2024, censoring data on September 23, 2024.…
Background Fostemsavir [FTR] is approved for use with other active antiretrovirals [ARVs] for treatment of heavily treatment-experienced people with HIV [PWH] and multi-drug resistance [MDR]. We described characteristics and treatment outcomes among PWH prescribed FTR in a real-world setting in the US. Methods PWH initiating FTR from July 2020 (FDA approval) to June 2023 identified…
Background Sustained expression of adeno-associated virus (AAV)-vectored anti-HIV-1 broadly neutralizing antibodies (bNAbs) could prevent and treat HIV-1 infection. However, durable expression of AAV-vectored bNAbs in vivo is limited by host immune responses, impeding efficacy studies in preclinical nonhuman primate (NHP) models. Programmed cell death protein (PD)-1 is an immune checkpoint protein on T cells that…